Make Money in Health Care the Easy Way

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you expect the health-care industry to thrive as our population ages, the Vanguard Health Care (NYSE: VHT  ) ETF could save you a lot of trouble. Instead of trying to figure out which companies will perform best, you can use this ETF to invest in scores of them simultaneously.

The basics
ETFs often sport lower expense ratios than their mutual fund cousins. The Health Care ETF's expense ratio -- its annual fee -- is a low 0.24%.

This ETF has performed well, beating the S&P 500 handily over the past three and five years. As with most investments, though, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver. With a low turnover rate of 10%, this fund isn't frantically and frequently rejiggering its holdings, as many funds do.

What's in it?
Several of this ETF's components made strong contributions to its performance over the past year. Pfizer (NYSE: PFE  ) , for example, gained 39%, and it may be getting a big boost from its Prevnar 13 vaccine, which can fight pneumonia. Some are speculating that it will execute a spin-off to unlock some value. UnitedHealth Group (NYSE: UNH  ) gained 63% over the past year, partly thanks to investors' faith that it will benefit from health-care reform as millions more Americans end up insured. Abbott Labs (NYSE: ABT  ) is up 13% since this time last year, but anticipation is building around its Humira drug, which might receive approval for a seventh indication, fighting ulcerative colitis.

Other companies didn't add as much to the ETF's returns last year, but could have an effect in the years to come. Celgene (Nasdaq: CELG  ) and Medco Health (NYSE: MHS  ) , for example, gained 10% and lost 9%, respectively. Celgene struggled against news that its main product, Remlivid, might be promoting secondary tumors in cancer patients -- but fellow Fool Brian Orelli felt the market overreacted to that. Pharmacy benefits manager Medco Health stands to benefit as blockbuster drugs' patents expire, since selling generic versions of those drugs will improve Medco's profit margins.

The big picture
Demand for health-care products and services isn't going away anytime soon. A well-chosen ETF can grant you instant diversification across the industry -- and make investing in and profiting from the sector that much easier.

ETFs can help you find the way to better investing results. To find some great ETF investing ideas, take a look at The Motley Fool's special free report, "3 ETFs Set to Soar During the Recovery."

Longtime Fool contributor Selena Maranjian holds no position in any company mentioned. Click here to see her holdings and a short bio. The Motley Fool owns shares of Abbott Labs, UnitedHealth Group, and MedcoHealth Solutions. Motley Fool newsletter services have recommended buying shares of MedcoHealth Solutions, Pfizer, UnitedHealth Group, and Abbott Labs, as well as creating a diagonal call position in UnitedHealth Group. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1507162, ~/Articles/ArticleHandler.aspx, 10/21/2016 11:19:25 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,066.51 -95.84 -0.53%
S&P 500 2,137.18 -4.16 -0.19%
NASD 5,244.53 2.70 0.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 11:03 AM
ABT $40.20 Down -0.55 -1.34%
Abbott Laboratorie… CAPS Rating: *****
CELG $99.04 Down -0.98 -0.98%
Celgene CAPS Rating: *****
MHS.DL $70.30 Down +0.00 +0.00%
Medco Health Solut… CAPS Rating: *****
PFE $32.30 Down -0.24 -0.74%
Pfizer CAPS Rating: ****
UNH $143.97 Down -1.10 -0.76%
UnitedHealth Group CAPS Rating: ****
VHT $127.88 Down -1.11 -0.86%
Vanguard Health Ca… CAPS Rating: ****